Clinical trials: Glofitamab
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Lymphoma
Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden
Glofitamab has shown efficacy and safety in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and has been approved for marketing in China.
- Trial name
- GLOHRT-01 (NCT06867536)
- Testing
- Glofitamab + Obinutuzumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Liling Zhang
Aggressive B-Cell Lymphoma
G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma
The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-GemOx as induction therapy in patients with Refractory/Relapsed Aggressive B-Cell Lymphoma.
- Trial name
- NCT07184788
- Testing
- Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy
- Volunteers
- 80 people
- Sponsor
- Navy General Hospital, Beijing
Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Mantle Cell Lymphoma
Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics
This trial will enroll patients with relapsed/refractory DLBCL and MCL, with the opportunity to receive single-agent glofitamab as early as the second-line.
- Trial name
- NCT07748364
- Testing
- Glofitamab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Joshua Brody
Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
CAR-T Followed by Bispecific Antibodies
The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells.
- Trial name
- NCT04889716
- Testing
- mosunetuzumab, glofitamab, obinutuzumab
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
B-Cell Lymphoma, Non-Hodgkin Lymphoma
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
This is a phase 1B, multi-center, dose-finding study of glofitamab administered in combination with obinutuzumab (Gazyva; [G]), rituximab (R) and standard doses of CHOP (G/R-CHOP or R-CHOP) in participants with r/r NHL and G/R…
- Trial name
- NCT03467373
- Testing
- Glofitamab, Obinutuzumab (G), Rituximab (R)
- Where
- 22 sites in United States, Australia and 7 more
- Volunteers
- 111 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma Refractory, Refractory Indolent Adult Non-Hodgkin Lymphoma
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
This study is a multicenter phase II trial including 2 cohorts of patients in Refractory/Relapse disease at least 1 month after CAR T-cells therapy: cohort 1: DLBCL patients cohort 2: PMBL, mantle cell lymphoma, transformed…
- Conditions
- Diffuse Large B-Cell Lymphoma Refractory, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Primary Mediastinal Large B-Cell Cell Lymphoma
- Trial name
- NCT04703686
- Testing
- Obinutuzumab, RO7082859
- Where
- 19 sites in France
- Volunteers
- 67 people
- Sponsor
- The Lymphoma Academic Research Organisation
B-cell Non-Hodgkin Lymphoma
A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
The purpose of this study is to assess the efficacy and safety in the real-world settings of glofitamab in combination with salvage therapy among Chinese adult patients with relapsed or refractory B-cell non-hodgkin lymphoma.
- Trial name
- GLOFTST (NCT06497452)
- Testing
- Glofitamab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Diffuse Large B-cell Lymphoma
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (Glofit-GemOx) compared with rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx) in patients with…
- Trial name
- NCT04408638
- Testing
- Obinutuzumab, Glofitamab, Rituxumab
- Where
- 63 sites in United States, Australia and 11 more
- Volunteers
- 270 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
This study aims to assess the efficacy and safety of the chemotherapy-light combination of glofitamab, polatuzumab vedotin and zanubrutinib (GPZ) in elderly patients with previously untreated diffuse large B-cell lymphoma.
- Trial name
- NCT07012980
- Testing
- Glofitamab, Polatuzumab Vedotin, Zanubrutinib
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Shanghai Zhongshan Hospital
DLBCL - Diffuse Large B Cell Lymphoma
Glofitamab in Chinese Patients With R/R DLBCL
This study will evaluate the safety and efficacy of glofitamab as a single agent in Chinese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of systemic therapy.
- Trial name
- NCT06481826
- Testing
- Glofitamab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Phase 2 Study, MCL
Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
to learn if giving glofitamab after treatment with BTKi-rituximab can help to control high-risk MCL.
- Conditions
- Phase 2 Study, MCL, BTKi, Rituximab
- Trial name
- NCT07257055
- Testing
- Acalabrutinib, Rituximab, Glofitamab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line treatment of patients with diffuse large B cell lymphoma (DLBCL) or…
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Lymphoma, Lymphoma, B-Cell
- Trial name
- TPG (NCT07502872)
- Testing
- Tafasitamab, Polatuzumab vedotin, Glofitamab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brown University
Large B-Cell Lymphoma (LBCL), High-grade B-cell Lymphoma
Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma
This investigator-initiated, single-center, single-arm, open-label Phase II study will evaluate the efficacy and safety of sonrotoclax in combination with glofitamab, gemcitabine, and oxaliplatin in adults with relapsed or…
- Trial name
- NCT07774234
- Testing
- Sonrotoclax, Glofitamab, Gemcitabine (1000 mg/m2)
- Where
- China
- Volunteers
- 39 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Non-Hodgkin's Lymphoma
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous…
- Trial name
- NCT03075696
- Testing
- Glofitamab, Obinutuzumab, Tocilizumab
- Where
- 34 sites in United States, Australia and 11 more
- Volunteers
- 940 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Non-Hodgkin
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This is a first-in human, open-label, Phase 1 dose-escalation study in order to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for intravenous (IV) and/or subcutaneous (SC) dosing schemes of…
- Trial name
- NCT05219513
- Testing
- RO7443904, Glofitamab, Obinutuzumab
- Where
- 9 sites in United States, Australia and 4 more
- Volunteers
- 53 people
- Sponsor
- Hoffmann-La Roche
DLBCL
Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL
Single-Arm Clinical Study of Zeprumetostat in Combination with Glofitamab + GemOx in Patients with Relapsed/ Refractory DLBCL
- Trial name
- NCT07643805
- Testing
- EZH2i+GLofit-GemOx
- Where
- China
- Volunteers
- 46 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
DLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma)
Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL
This prospective study was conducted to evaluate the efficacy and safety of hypofractionated radiotherapy combined with granulocyte-macrophage colony-stimulating factor, pomalidomide and glofitamab in patients with newly…
- Trial name
- NCT07749365
- Testing
- hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab
- Where
- China
- Volunteers
- 53 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
This phase Ib trial tests the safety and side effects of glofitamab after pre-treatment with obinutuzumab and how well they work in treating patients with central nervous system (CNS) lymphoma.
- Trial name
- NCT06922604
- Testing
- Biospecimen Collection, Computed Tomography, Glofitamab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Non-Hodgkin Lymphoma
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.
- Trial name
- NCT05169515
- Testing
- SC Mosunetuzumab, IV Glofitamab, Iberdomide
- Where
- 25 sites in United States, Israel and 3 more
- Volunteers
- 121 people
- Sponsor
- Hoffmann-La Roche
Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
This phase I/II trial tests the safety and effectiveness of glofitamab (with obinutuzumab pretreatment), venetoclax, and lenalidomide in treating patients with newly diagnosed, high risk mantle cell lymphoma.
- Conditions
- Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
- Trial name
- NCT05861050
- Testing
- Biopsy, Biospecimen Collection, Bone Marrow Biopsy
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- City of Hope Medical Center